No.

Project title

Source of finding

years

1

Anti-atherosclerotic Effects of Prostacyclin Analogues

The Wellcome Research Laboratories, UK

1983

2

Direct Assessment of Potential Anti-Atherosclerotic Drugs Using Human Atherosclerotic Cells

Knoll AG, Germany

1986

3

Direct Assessment of Anti-Atherosclerotic and Anti-Atherogenic Effects of Mevinolin Using Human Aortic Cells (Two Parameters)

Merck Sharp & Dome Co., USA

1987

4

Use of Ex Vivo Cellular Model for the Study of MEVINOLIN Monotherapy Effect on Blood Serum Atherogenicity

Merck Sharp & Dome Co.

1989

5

Direct Assessment of Anti-Atherosclerotic Effects of Drugs and Chemicals Using Human Aortic Cells

Sandoz Ltd., Switzerland

1989

6

Investigation of Captopril Atherosclerosis-Related Effects Using Primary Culture of Human Aortic Cells

Squibb-Heyden Int., Germany

1990

7

Study of the Effect of Celiprolol Monotherapy on Blood Serum Atherogenicity

The Upjohn Company, USA

1991

8

Direct Assessment of Anti-Atherosclerotic and Anti-Atherogenic Effects of Perindoprilat Using Human Aortic Cells

Les Laboratoires Servier, France

1991

9

Study of the effect of Perindopril monotherapy on blood serum atherogenicity

Les Laboratoires Servier, France

1992

10

The Investigation of Direct Antiatherogenic (Preventive) and Antiatherosclerotic (Therapeutic) Effects of ACAT Inhibitors

SmithKline Beecham Pharmaceuticals, UK

1992

11

Direct Assessment of Anti-Atherosclerotic and Anti-Atherogenic Effect of Garlic Using Human Aortic Cells

Lichtwer Pharma GmbH, Germany

1992

12

Examination of Immunomodulation Properties of Garlic Powder

Lichtwer Pharma GmbH, Germany

1992

13

Direct Assessment of Anti-Atherosclerotic and Anti-Atherogenic Effects of the Drugs Using Human Aortic Cells

Asta Medica AG, Sweden

1993

14

In-Depth Investigation of Garlic Powder Extract Atherosclerosis-Related Effects

Lichtwer Pharma GmbH, Germany

1993

15

Direct Assessment of Anti-Atherosclerotic and Anti-Atherogenic Effects of Lipostabil Using Human Aortic Cells In Vitro

Phone-Poulenc Rorer GmbH, Germany

1993

16

The In Vitro Investigation of Antiatherosclerotic Effect of Moxonidine

Beiersdorf-Lilly GmbH, Germany

1993

17

Investigation of atherogenicity of blood serum of patients treated with Lipostabil

Phone-Poulenc Rorer GmbH, Germany

1993

18

Use of Ex Vivo Cellular Model for the Study of Sapec Effect on Blood Serum Atherogenicity

Lichtwer Pharma GmbH, Germany

1994

19

The Ex Vivo Investigation of Antiatherosclerotic Effect of Lipostabil

Phone-Poulenc Rorer GmbH, Germany

1994

20

The in Vitro Investigation of Antiatherosclerotic and Antiatherogenic Effects of Amlodipine

Pfizer International Pharmaceuticals, USA

1994

21

Use of Ex Vivo Cellular Model for the Study of Amlodipine Effect on Blood Serum Atherogenicity

Pfizer International Pharmaceuticals, USA

1994

22

Role of modified low density lipoproteins and anti-lipoprotein antibodies in atherosclerosis development

Russian Foundation of Basic Sciences , Russian Federation

1994

23

The Study of Garlic Active Components Testing in In Vitro Cellular System

Lichtwer Pharma GmbH

1995

24

Anti-Atherosclerosis-Related Effects of Saterinone and BDF 9196

Beiersdorf-Lilly GmbH, Germany

1995

25

Use of Ex-Vivo Cellular Model for the Study of Anti-Atherosclerosis-Related Effects of Amlodipine Plus Lovastatin Combination

Pfizer International Pharmaceuticals, USA

1995

26

Study of Allicor effect on coagulate system in patients with atherosclerosis and hypercoagulation I-II degree

INAT-Farma Ltd., Russian Federation

1996

27

Metabolism of multiple-modified low density lipoproteins in human aortic cells

Russian Foundation of Basic Sciences , Russian Federation

1997-1999

28

Study of Allicor glucose-lowering effect in diabetes mellitus type II (double blind placebo-controlled study)

INAT-Farma Ltd., Russian Federation

1998

29

Atherosclerosis monitoring and atherogenicity reduction (double blind placedo-controlled multi-center study

INAT-Farma Ltd., Russian Federation

1998-2003

30

Multicenter open prospective study of hypolipidemic efficacy and safety of oral use of Allicor in patients with moderate hyperlipidemia (phase III)

INAT-Farma Ltd., Russian Federation

2004-2005